Novo Nordisk ADR (NYSE: NVO) kicked off on Friday, down -0.01% from the previous trading day, before settling in for the closing price of $111.95. Over the past 52 weeks, NVO has traded in a range of $94.73-$148.15.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 14.25% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 23.01%. With a float of $3.34 billion, this company’s outstanding shares have now reached $3.38 billion.
In an organization with 63370 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 84.53%, operating margin of 43.26%, and the pretax margin is 43.77%.
Novo Nordisk ADR (NVO) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – General Industry. The insider ownership of Novo Nordisk ADR is 0.02%, while institutional ownership is 10.09%.
Novo Nordisk ADR (NVO) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported 0.73 earnings per share (EPS), higher than consensus estimate (set at 0.73) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.9 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.21% during the next five years compared to 16.48% growth over the previous five years of trading.
Novo Nordisk ADR (NYSE: NVO) Trading Performance Indicators
Take a look at Novo Nordisk ADR’s (NVO) current performance indicators. Last quarter, stock had a quick ratio of 0.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.99. Likewise, its price to free cash flow for the trailing twelve months is 31.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.91, a number that is poised to hit 0.88 in the next quarter and is forecasted to reach 4.18 in one year’s time.
Technical Analysis of Novo Nordisk ADR (NVO)
Let’s dig in a bit further. During the last 5-days, its volume was 7.54 million. That was better than the volume of 4.36 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 49.44%. Additionally, its Average True Range was 2.42.
During the past 100 days, Novo Nordisk ADR’s (NVO) raw stochastic average was set at 11.49%, which indicates a significant decrease from 39.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 10.91% in the past 14 days, which was lower than the 33.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $124.20, while its 200-day Moving Average is $128.27. However, in the short run, Novo Nordisk ADR’s stock first resistance to watch stands at $112.71. Second resistance stands at $113.48. The third major resistance level sits at $113.94. If the price goes on to break the first support level at $111.48, it is likely to go to the next support level at $111.02. Assuming the price breaks the second support level, the third support level stands at $110.25.
Novo Nordisk ADR (NYSE: NVO) Key Stats
The company with the Market Capitalisation of 373.70 billion has total of 4,487,532K Shares Outstanding. Its annual sales at the moment are 33,724 M in contrast with the sum of 12,151 M annual income. Company’s last quarter sales were recorded 9,821 M and last quarter income was 2,893 M.
